Medical R&D news, white papers, reports, and events from PharmaLeaders. New content daily, on our website and delivered right to your inbox.
Sudler & Hennessey Group Acquires Viscira Acquisition Adds Innovative New Media Communications and Technology Horsepower to the Company NEW YORK, March 24, 2016 /PRNewswire/ — Sudler & Hennessey Group, a leading global healthcare communications network, is pleased to announce the acquisition of Viscira, a leader in digital marketing and cutting-edge media in the healthcare space. Viscira develops visually-stunning, interactive solutions that provide unique, ... Read More
Omnichannel Marketing: Shaping the Future of Patient Engagement King of Prussia, PA, 3/28/16– Omnichannel marketing, perhaps the latest business buzz word, isn’t just a crafty marketing scheme designed to repurpose existing strategies into something new and different. Truth is, omnichannel marketing is an authentic, unique and effective approach to communications, and it’s been a growing trend a lot longer than many realize. Consider Collaborative ... Read More
New app brings gamification to medicine adherence to cut waste and save cash For immediate release 9 March 2017 The launch of new app Mega Meds is tackling the issue of medical adherence through combining medicine management with engaging, fun games. The trend for gamification has been growing but the unique application of it for encouraging better management of medicine could save the global healthcare industry billions every year. The cost ... Read More
Teewinot Life Sciences and Noramco sign letter of intent to produce cannabinoids with CannSynthesis™ biocatalysis technology Teewinot Life Sciences (Teewinot), the market leader in biocatalytic technologies for the production of pharmaceutical-grade cannabinoids, and Noramco, a global leading producer of controlled-substance active pharmaceutical ingredients (APIs), today signed a letter of intent to enter the commercial cannabinoids market using proprietary CannSynthesis™ technology. The agreement provides Noramco access to Teewinot’s patent protected processes for ... Read More
The Case for Intelligent Design (and Infrastructure) in Life Science Biologics R&D New White Paper from IDC Health Insights examines industry trends, new challenges and emerging capabilities in biologics. With many recent blockbuster patents expiring, the pharmaceutical industry finds itself in the middle of a transformation. Leading life science organizations are updating their business strategies to include the pursuit of a new market opportunity – the discovery and development ... Read More
Pediatric Gene Therapy The European approvals of Glybera® in 2012 and Strimvelis® in 2016 seem likely to be the vanguard of the therapeutic revolution heralded by the decoding of the human genome. Both of these treatments originated from academic centers of excellence and became the subjects of agreements with pharmaceutical companies (Uniqure/Chiesi and GSK, respectively) with the experience ... Read More